AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Google for Healthcare
Gunjan Bhardwaj chose Germany as the place to launch his advanced search and discovery solution. His company assists the healthcare industry by organizing and analyzing vast amounts of data using artificial intelligence.
Since its establishment in 2011, the highly specialized search and analysis engine Innoplexus has become a major player in the healthcare sector. Based in Eschborn, Germany, the company provides valuable information for pharmaceutical and biotechnology companies as well as researchers and doctors. By enabling users to access the most recent life science data much faster and more efficiently than previously possible, and by connecting all the different data points from structured and unstructured data, it also serves as a research and development accelerator, especially for pharmaceuticals.
Gunjan Bhardwaj, founder and CEO of the Innoplexus group, had always been interested in Germany as a business location. After graduating from the Indian Institute of Technology (IIT) in Mumbai in 2005, he had the chance to travel to Germany on a German Academic Exchange Service (DAAD) scholarship. He attended Pforzheim University of Applied Sciences in Baden-Württemberg before moving to the consultancy firm EY in Stuttgart, where he headed up a global performance think tank.
Organizing data for life science
Innoplexus grew out of Bhardwaj’s efforts to find specific medical information after a friend had been diagnosed with cancer. Using artificial intelligence (AI), machine learning and blockchain-based analytics, the search system can track, assess, organize, connect and analyze all the available information on specific diseases and therapies worldwide. “Innoplexus crawls and aggregates the entire published and unpublished digital universe in life science in real time and provides continuous analytics to pharmaceutical companies, research centers, hospitals and, hopefully very soon, patients,” explains Bhardwaj in an article on entrepreneur.com. The problem is not the availability of data in healthcare but the fact it is often unstructured and disordered, which is a “huge problem in drug discovery,” he tells The Pharma Letter. That, he says, hampers research and creates inefficiency.
300+
Number of employees across Innoplexus facilities (Germany, India, U.S.)
AI-based global search solutions
Expanding on the need for such a platform at a TED talk in Darmstadt last year, Bhardwaj pointed out that by 2020, medical knowledge was expected to double every 73 days at the present rate, meaning that medical data at the beginning of 2020 would increase more than 32 times by the end of that year.
The next step for Innoplexus, which also has offices in the U.S. and India, is to expand the use of its technology and introduce it into other industries with the overarching goal of becoming a leading provider of AI analytics solutions. This year Bhardwaj is planning to branch out into the banking and financial sector with a comparable product.
97%
of all public life science information covered is covered by the Ontosight engine.
Originally published on Market Germany.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…